Stock info Novartis | Filter  Basic-Info

Stock: Novartis (Swiss large cap), ISIN: CH0012005267

Last Price 86.72 Max Price 94.40
Min Price 77.96 1 Year return 8.02
Avg. Target 95.80 Expected Return 10.47 %
Sector Health Care Subsector Pharmaceuticals
Sell 2 Rating Star full 12x12Star full 12x12Star full 12x12
Hold 0 Concensus Cons sellCons buy
Buy 3
Annual report 2015

Loading...

Contact info:Zip Code: CH-4002 BaCity: BaselCountry: SwitzerlandPhone: +41 61 324 11 11Email: investor.relations@novartis.comWebsite: www.novartis.comCEO: Joseph Jimenez

Sector Review Novartis

Loading...
Year Turnover Total sector Market share
2019 48,624 615,634 7.90 %
2020 49,898 638,070 7.82 %
2021 52,877 727,968 7.26 %
2022 51,742 787,273 6.57 %
2023 0 0 0.00 %

Advice Novartis

Date Label Bank Label Stock Label Advice Label Price Label Diff Label
January 15, 2024 UBS Novartis Buy 104.00 16.62 %
December 30, 2023 Deutsche Bank Novartis Hold 110.00 21.16 %
November 06, 2023 Morgan Stanley Novartis Buy 92.00 5.74 %
October 24, 2023 Barclays Novartis Sell 85.00 -2.02 %
October 12, 2023 Jefferies & Co. Novartis Buy 100.00 13.28 %
July 14, 2023 HSBC Novartis Buy 110.00 21.16 %
April 26, 2023 JP Morgan Novartis Sell 92.00 5.74 %
October 07, 2023 UBS Novartis Hold 90.00 3.64 %
July 11, 2023 Morgan Stanley Novartis Buy 93.00 6.75 %
June 06, 2023 Deutsche Bank Novartis Hold 110.00 21.16 %
May 03, 2023 Jefferies & Co. Novartis Buy 105.00 17.41 %
April 12, 2023 Barclays Novartis Sell 85.00 -2.02 %
March 28, 2023 Jefferies & Co. Novartis Buy 100.00 13.28 %
March 28, 2023 Deutsche Bank Novartis Hold 80.00 -8.40 %
February 09, 2023 Deutsche Bank Novartis Sell 70.00 -25.67 %
February 09, 2023 Berenberg Novartis Hold 80.00 -9.96 %
January 03, 2023 JP Morgan Novartis Sell 85.00 0.19 %
December 29, 2022 Barclays Novartis Sell 75.00 -13.12 %
December 05, 2022 Stifel Novartis Buy 97.00 12.25 %
December 01, 2022 Beleggers Belangen Novartis Hold
October 26, 2022 JP Morgan Novartis Sell 78.00 -9.12 %
October 08, 2022 Goldman Sachs Novartis Buy 106.00 11.59 %
October 08, 2022 Deutsche Bank Novartis Sell 70.00 -33.87 %
October 07, 2022 UBS Novartis Hold 80.00 -17.14 %
September 18, 2022 JP Morgan Novartis Sell 81.00 -13.90 %
September 15, 2022 Credit Suisse Novartis Sell 78.00 -13.22 %
September 14, 2022 Berenberg Novartis Hold 80.00 -10.39 %
August 28, 2022 Goldman Sachs Novartis Buy 107.00 16.15 %
May 08, 2022 Morgan Stanley Novartis Buy 94.00 3.05 %
April 28, 2022 UBS Novartis Hold 88.00 -1.72 %
April 28, 2022 Deutsche Bank Novartis Sell 80.00 -11.89 %
April 27, 2022 Barclays Novartis Sell 85.00 -5.31 %
April 27, 2022 UBS Novartis Hold 85.00 -5.31 %
April 27, 2022 JP Morgan Novartis Sell 80.00 -11.89 %
April 26, 2022 Jefferies & Co. Novartis Buy 100.00 11.09 %
April 05, 2022 ABN AMRO Novartis Hold
February 17, 2022 Liberum Novartis Hold 85.00 5.39 %
January 26, 2022 Liberum Novartis Hold 87.00 2.23 %
January 07, 2022 UBS Novartis Buy 82.00 -3.54 %
January 01, 2022 Goldman Sachs Novartis Buy 106.00 20.04 %



News Novartis

Extreme dividend yield Novartis

Huge dividend Novartis Investors in Novartis can expect a huge dividend payment. Based on the recent analysts' consensus the stock now has one of the highest dividend returns of the Swiss market. Per share the analysts expect a dividend of 3.6 CHF per share....

Novartis now in top highest dividend yields in Switzerland

Investors in Novartis can expect a huge dividend payment. Based on the recent analysts' consensus the stock now has one of the highest dividend returns of the Swiss market. Per share the analysts expect a dividend of 3.5 CHF per share. The dividend yield is then...

Novartis wins FDA approval for prostate cancer therapy

On Wednesday, the U.S. Food and Drug Administration (FDA) granted the approval for Swiss pharma giant, Novartis (NYSE:NVS) to market its radioligand therapeutic agent Pluvicto as a treatment for certain adult patients with prostate cancer. According to...

Novartis expands optogenetics portfolio with acquisition of Arctos Medical

Novartis (NYSE:NVS) has acquired Arctos Medical, adding a pre-clinical optogenetics-based AAV gene therapy program and Arctos' proprietary technology to its ophthalmology portfolio. Financial details are not disclosed. Arctos developed its technology...

Novartis ends Wet AMD trial for Beovu citing safety concerns

Novartis (NYSE:NVS) announced the termination of its Phase 3 MERLIN study that was designed to evaluate Beovu (brolucizumab) 6 mg versus Regeneron's EYLEA (Aflibercept) 2 mg in patients with wet age-related macular degeneration (AMD). Announcing year one...

Annual reports Novartis

2017 2018 2019 2020 2021

Profile Novartis

Novartis

(CH0012005267)/ NOVN

The past year was a good year for Novartis investors

Over the last 12 months (from December 2015 till December 2016), that were loss-making period for the investors in Novartis, the stock lost around 13 percent. The period between August 2011 and August 2016 was a good period for the investors. The stock rose around 52 percent. Novartis's revenues between 2011 and 2015 were relatively steady and moved between 52,7 billion CHFF and 50,45 billion CHFF. Novartis's net results between 2011 and 2015 were relatively steady and moved between 10,06 billion CHFF and 8,61 billion CHFF.

Novartis's head office is located in Basel. Novartis is mostly active in the pharmaceutical sector. Novartis is being led by CEO Joseph Jimenez. The past 10 years the (international) industry gained at around 75 percent. As from 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.

The Swiss company paid out dividends in the past 5 years. Over the past 5 years Novartis's dividend yield was at around 12,32 percent per year.

Novartis had about 133,41 thousand employees at the end of 2015.

Novartis' balance mostly consists of equity

At the end of 2015 the Swiss company had a balance sheet of 131,79 billion CHFF. The total debt of the pharmaceutical company was at the end of 2015 54,61 billion CHFF, which equals around 41,43 percent of the total balance sheet. The Swiss company's price/earnings-ratio was 26. So the market valued the stock at 26 times the 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the Swiss stock can be seen as a value stock.

At the end of 2015 the Swiss company's market capitalization equaled around 205,94 billion CHFF. At the end of 2015 around 2,4 billion stocks were listed.

All of Novartis's annual reports are stored here. More information about Novartis can be found it's website. .


Results Novartis

Results
2015
2016
2017
2018
2019
2020
Revenue
50,359
49,386
50,135
53,166
48,624
49,898
Costs
32,576
42,674
42,432
40,555
36,892
41,826
Profit
17,783
6,712
7,703
12,611
11,732
8,072
Margin of profit
35.31
13.59
15.36
23.72
24.13
16.18
ROI
23.08
8.97
10.39
16.04
21.15
14.26

Balance Novartis

Balance
2015
2016
2017
2018
2019
2020
Equity
77,046
74,832
74,168
78,614
55,474
56,598
Debt
54,510
55,292
58,911
66,949
62,896
71,180
Total assets
131,556
130,124
133,079
145,563
118,370
127,778
Solvency
58.57
57.51
55.73
54.01
46.86
44.29
Cash
5,302
7,546
9,347
15,718
11,234
11,293
Cashflow
11,897
11,475
12,621
14,272
13,625
13,650
Employees
0
0
0
0
0
Revenue per employee
0.0
0.0
0.0
0.0
0.0
Cashflow / Debt
0.22
0.21
0.21
0.21
0.22
0.19

Details Novartis

Details
2016
2017
2018
2019
2020
Price
76.73
65.50
72.84
74.29
91.90
Eps
2.80
3.25
5.38
5.06
3.52
Price/earnings-ratio
27.40
20.15
13.54
14.68
24.64
Dividend
2.70
2.87
2.90
3.05
3.39
Dividend %
3.52 %
4.38 %
3.98 %
4.11 %
3.91 %
Payout %
0.96
0.88
0.54
0.60
0.96
Book value
31.52
32.00
34.01
24.49
25.08
Market to book
0.41
0.49
0.47
0.33
0.29
Cashflow per stock
4.83
5.45
6.18
6.02
6.05
Stocks
2,374
2,317
2,311
2,265
2,257
Market Cap
182.161.55
151.793.40
168.345.62
168.267.59
195.711.43

Dividend Novartis


Price info Novartis

Date
Price
22 Mar 2024
86.72
18 Mar 2024
85.53
15 Mar 2024
86.80
12 Mar 2024
87.59
11 Mar 2024
88.11
09 Mar 2024
88.11
07 Mar 2024
91.06
01 Mar 2024
89.49
29 Feb 2024
90.00
27 Feb 2024
91.36
22 Feb 2024
90.04
21 Feb 2024
90.77
20 Feb 2024
89.56
15 Feb 2024
87.80
14 Feb 2024
88.02
13 Feb 2024
87.68
09 Feb 2024
87.97
08 Feb 2024
87.97
07 Feb 2024
90.09
06 Feb 2024
90.36
05 Feb 2024
89.80
01 Feb 2024
89.40
31 Jan 2024
89.40
30 Jan 2024
92.91
27 Jan 2024
92.46
25 Jan 2024
93.53
24 Jan 2024
93.50
23 Jan 2024
94.40
16 Jan 2024
92.00
11 Jan 2024
91.55